Meningococcal vaccine - Xenova

Drug Profile

Meningococcal vaccine - Xenova

Alternative Names: MEN-B; Meningitis vaccine - Xenova

Latest Information Update: 29 Jul 2004

Price : $50

At a glance

  • Originator Xenova Group
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Meningococcal infections

Most Recent Events

  • 29 Jul 2004 Discontinued - Preclinical for Meningococcal infections in United Kingdom (unspecified route)
  • 13 Dec 2002 A candidate vaccine against meningitis B has entered preclinical research
  • 04 Sep 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top